USANA Health Sciences (NYSE:USNA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.07, Yahoo Finance reports. The company had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same period last year, the company posted $0.59 earnings per share. USANA Health Sciences updated its FY 2024 guidance to 2.450-2.450 EPS.
USANA Health Sciences Stock Performance
USNA stock traded up $1.31 on Wednesday, hitting $35.79. 37,505 shares of the company’s stock were exchanged, compared to its average volume of 79,717. The firm has a 50 day moving average price of $38.02 and a two-hundred day moving average price of $42.59. USANA Health Sciences has a 12-month low of $34.15 and a 12-month high of $55.45. The stock has a market cap of $681.84 million, a P/E ratio of 10.55, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on USNA. DA Davidson cut their price target on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th.
Insider Buying and Selling at USANA Health Sciences
In other news, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now directly owns 2,503 shares in the company, valued at approximately $111,208.29. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is owned by insiders.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
- Five stocks we like better than USANA Health Sciences
- Why Invest in 5G? How to Invest in 5G Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Compound Interest and Why It Matters When Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- When to Sell a Stock for Profit or Loss
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.